## Atypical Pneumonia & Macrolide Selection ### Clinical Context Atypical pneumonia (caused by *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, or *Legionella*) presents with subacute onset, bilateral interstitial infiltrates, and systemic symptoms disproportionate to chest findings. ### Why Azithromycin is First-Line **Key Point:** Macrolides are the gold standard for atypical pneumonia because they achieve excellent intracellular penetration and cover all three major atypical pathogens. **High-Yield:** Azithromycin is preferred over erythromycin due to: - Better tissue penetration and lung bioavailability - Longer half-life (allows once-daily or 3-day dosing) - Superior tolerability (less GI upset than erythromycin) - Convenient dosing: 500 mg on day 1, then 250 mg daily × 4 days ### Macrolide Coverage in Atypical Pneumonia | Pathogen | Azithromycin | Erythromycin | Fluoroquinolone | Beta-lactam | |----------|--------------|--------------|-----------------|-------------| | *Mycoplasma pneumoniae* | ✓ | ✓ | ✓ | ✗ | | *Chlamydia pneumoniae* | ✓ | ✓ | ✓ | ✗ | | *Legionella pneumophila* | ✓ | ✓ | ✓ | ✗ | **Clinical Pearl:** Beta-lactams (ceftriaxone, amoxicillin) are ineffective against atypical organisms because these pathogens lack a cell wall or have unusual cell wall structures. ### Why Fluoroquinolones Are Not First-Line While fluoroquinolones (levofloxacin, moxifloxacin) cover atypical pathogens, they are reserved for: - Severe pneumonia requiring hospitalization - Intolerance to macrolides - Immunocompromised patients Macrolides remain preferred in community-acquired atypical pneumonia due to cost, safety profile, and established efficacy. **Warning:** Do not confuse atypical pneumonia with typical bacterial pneumonia (caused by *Streptococcus pneumoniae*, *Haemophilus influenzae*), which requires beta-lactams or fluoroquinolones.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.